| Ezetimibe and reactive oxygen species. | |
| | |
MedLine Citation:
|
PMID: 21044015 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
Ezetimibe is a potent inhibitor of cholesterol absorption that has been approved for the treatment of hypercholesterolemia. Statin, 3-hydroxy-3 methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, is an inhibitor of cholesterol synthesis. Statin is the first-choice drug to reduce low-density lipoprotein (LDL)-cholesterol for patients with hypercholesterolemia, due to its strong effect to lower the circulating LDL-cholesterol levels. Because a high dose of statins causes concern about rhabdomyolysis, it is sometimes difficult to achieve the guideline-recommended levels of LDL-cholesterol in patients with high LDL-cholesterol treated with statin monotherapy. Ezetimibe has been reported to reduce LDL-cholesterol safely with both monotherapy and combination therapy with statins. Ezetimibe is especially expected to be the best pharmacological option for the treatment of patients unable to achieve LDL-cholesterol goals with statins. Reactive oxygen species (ROS) are produced at low levels to maintain physiological redox balance. Oxidative stress results when ROS production exceeds the ability of cells to detoxify ROS. Overproduction of ROS damages cellular components, including lipids, leading to decline in physiological function and cell death. Oxidative stress exacerbates atherosclerosis, the major risk factor for coronary artery disease and ischemic stroke, at every step involves the accumulation of oxidized LDL in the arteries, leading to foam cell formation, plaque development, and plaque rupture. This review focuses on the recent findings of ezetimibe-related atheroprotective effects in vasculature. Moreover, known and proposed mechanisms of how ezetimibe could improve ROS-induced pro-atherosclerotic conditions in vasculature are discussed; these effects may help to explain the mechanisms by which ezetimibe may protect vascular from atherosclerosis. |
| | |
Authors:
|
Minako Yamaoka-Tojo; Taiki Tojo; Naonobu Takahira; Takashi Masuda; Tohru Izumi |
Related Documents
:
|
12901025 - Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety. 2065035 - Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects.... 11472705 - Correlation of non-high-density lipoprotein cholesterol with apolipoprotein b: effect o... 9149215 - Beneficial effect of lovastatin on sphincter of oddi dyskinesia in hypercholesterolemia... 9397245 - Effect of doxazosin on endothelial dysfunction in hypercholesterolemic/antioxidant-defi... 16467655 - Effects of changes in sodium balance on plasma and kidney angiotensin ii levels in anes... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Current vascular pharmacology Volume: 9 ISSN: 1875-6212 ISO Abbreviation: Curr Vasc Pharmacol Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2010-11-16 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101157208 Medline TA: Curr Vasc Pharmacol Country: United Arab Emirates |
Other Details:
|
Languages: eng Pagination: 109-20 Citation Subset: IM |
Affiliation:
|
Department of Rehabilitation, Kitasato University School of Allied Health Sciences, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0373, Japan. myamaoka@med.kitasato-u.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Ezetimibe and vascular inflammation.
Next Document: Novel role of NPC1L1 in the regulation of hepatic metabolism: potential contribution of ezetimibe in...